Core Insights - MetaVia Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, with key developments in obesity and liver disease treatments [3]. Company Overview - The company is developing DA-1726, a novel oxyntomodulin (OXM) analogue, aimed at treating obesity. It acts as a dual agonist for glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR), potentially leading to superior weight loss compared to selective GLP1R agonists [3]. - DA-1726 has shown best-in-class potential in a Phase 1 multiple ascending dose trial, demonstrating effectiveness in weight loss, glucose control, and waist reduction [3]. - MetaVia is also developing DA-1241, a G-protein-coupled receptor 119 (GPR119) agonist, for treating Metabolic Dysfunction-Associated Steatohepatitis (MASH). Pre-clinical studies indicate its positive effects on liver inflammation, lipid metabolism, weight loss, and glucose metabolism [3]. - In a Phase 2a clinical study, DA-1241 exhibited direct hepatic action alongside glucose-lowering effects, reducing hepatic steatosis, inflammation, and fibrosis [3]. Conference Participation - President and CEO Hyung Heon Kim will present at the H.C. Wainwright Liver Disease Virtual Conference on October 21-22, 2025, with CFO Marshall H. Woodworth participating in one-on-one meetings [1][2].